Independently of JAK status or of MPN subtype (myelofibrosis or PV), several cytokines were reduced after ruxolitinib treatment such as IL1Ra, IL6, IL8, TNFα, and bFGF [3, 4]. This evidence concerns the gene IL6 and acquired polycythemia vera.